title: Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
abstract: Uncontrolled cell division is a defining characteristic of cancer cells. Cyclin-dependent kinases (Cdks) are critical regulators of cell cycle progression. Deregulated Cdk activities as a result of gene amplification, translocation, or point mutations of Cdks or cyclins, have been reported in a majority of human cancers. These kinases, therefore, represent potential therapeutic targets for the treatment of cancer. In this review, we offer an overview of Cdk functions in driving cell cycle progression and transcriptional regulation, a highlight of the DNA damage checkpoints, and an outline of the most relevant Cdk inhibitors currently in clinical trials with an emphasis on the Cdk inhibitors used for treatment of multiple myeloma.
authors.affiliation: Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Loredana
authors.initials: L
authors.lastname: Santo
authors.affiliation: Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Ka Tat
authors.initials: KT
authors.lastname: Siu
authors.affiliation: Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. Electronic address: NRAJE@mgh.harvard.edu.
authors.forename: Noopur
authors.initials: N
authors.lastname: Raje
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects* / Q000235:genetics; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D004249:DNA Damage; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D018844:Cyclin-Dependent Kinases